Gut Inflammation in Primary Sclerosing Cholangitis and Autoimmune Sclerosing Cholangitis-Contrasting Pattern of Liver-gut Cross Talk  by Navaneethan, Udayakumar
EBioMedicine 2 (2015) 1310–1311
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomed ic ine.comCommentaryGut Inﬂammation in Primary Sclerosing Cholangitis and Autoimmune
Sclerosing Cholangitis-Contrasting Pattern of Liver-gut Cross TalkUdayakumar Navaneethan ⁎
Center for Interventional Endoscopy, Florida Hospital, University of Central Florida College of Medicine, Orlando, FL, USADOI of original article: http://dx.doi.org/10.1016/j.ebi
⁎ Corresponding author at: Center for Interventional En
Invasive Surgery, Florida Hospital, 601 E Rollins Street, Or
E-mail address: udhaykumar81@gmail.com.
http://dx.doi.org/10.1016/j.ebiom.2015.09.046
2352-3964/© 2015 The Author. Published by Elsevier B.Va r t i c l e i n f oArticle history:
Received 27 September 2015
Accepted 27 September 2015
Available online 30 September 2015
histologicallymild, the patients had comparable fecal calprotectin levels
as patients with IBD alone. However, the ﬁndings in the small bowel on
capsule endoscopy were different between these entities. Seven of the
capsule endoscopy studies in the patients with AISC were abnormal
with mucosal breaks which were seen predominantly in the distal
ileum. On the other hand, all of the capsule endoscopy studies in the
PSC patients were normal except for one patient who had features ofPrimary sclerosing cholangitis (PSC) is a chronic inﬂammatory dis-
ease of the biliary tree characterized by ﬁbrosis and stricturing of the
bile ducts leading to cirrhosis (Navaneethan and Shen, 2010). The coex-
istence of inﬂammatory bowel disease (IBD) in 70–80% of PSC patients
suggests that immune dysregulation and/or loss of tolerance to gut bac-
teria may be associated with or promote the disease process
(Navaneethan and Shen, 2010; Loftus et al., 2005; Navaneethan,
2014). IBD in patients with concomitant PSC demonstrates a distinct
pattern of clinical phenotype with a higher prevalence of rectal sparing,
backwash ileitis, pancolitis, lower degree of inﬂammation and higher
risk for colorectal neoplasia (Loftus et al., 2005; Navaneethan, 2014).
Thus, IBD in patients with PSC could be considered a distinct clinical en-
tity from classic ulcerative colitis (UC) and Crohn's disease (CD). Auto-
immune sclerosing cholangitis (AISC) is a distinctive subset of patients
who have clinical overlap features with PSC and autoimmune hepatitis
(Floreani et al., 2005; Gregorio et al., 2001). The clinical presentation
and the phenotype of colitis in patients with AISC are not known. Un-
derstanding the clinical phenotype may help understand the gut-liver
axis and provide rational diagnostic andmanagement approach and de-
cisions when confronted with an IBD patient with concomitant liver
disease.
In this issue of EBioMedicine, Bjarnason and colleagues at Kings Col-
lege studied intestinal inﬂammation associated with AISC and com-
pared the ﬁndings with those seen in patients with PSC-associated
colitis and patients with IBD alone (Bjarnason et al., 2015). The micro-
scopic ﬁndings of the colonic mucosa were identical between patients
with AISC and PSC. The inﬂammation was almost invariably more pro-
nounced in the right colon and there were no features suggestive of
CD. The authors demonstrated that although the inﬂammation isom.2015.08.041.
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lbackwash ileitis. An interesting observation of the study was that one
third of the patients with AISC had small bowel involvement on capsule
endoscopy. How do we explain these results and what do they mean?
This study highlights the contrasting pattern of liver-gut cross talk in
PSC and AISC. What is the signiﬁcance of these mucosal breaks in the
small bowel?
The pathogenesis of PSC in IBD has been suggested to be related to
IBD and inﬂammation in the portal tracts. This ‘leaky gut’may be related
to gut microbiota contributing to the pathogenesis of PSC (Terjung and
Spengler, 2009). Bacterial translocation or absorption of bacterial endo-
toxins into the portal circulation, through a chronically inﬂamed bowe
with the activation of Kupffer cell,may contribute to the pathogenesis o
PSC (Terjung and Spengler, 2009). Another possible liver–gut crosstalk
in PSC and UC pathogenesis has been suggested to be related to the
enterohepatic circulation of lymphocytes. Gut-activated T-lymphocytes
in UCpatientsmay contribute to bile duct inﬂammation because the ad-
hesion molecule proﬁles of gut and liver endothelium are similar
(Adams and Eksteen, 2006). Since both PSC and AISC share distinct au-
toantibodies such as atypical perinuclear antineutrophil cytoplasmic
antibodies, cross-recognition between microbial antigens in the gut
and the immune system through pattern recognition receptors may
play a role in the liver–gut crosstalk (Adams and Eksteen, 2006;
Liaskou et al., 2011). Since this phenomenon involves gut and the
liver, any part of small bowel or colon inﬂammation may be related to
the pathogenesis of PSC. However, the pathogenesis of liver disease in
PSC is only related to colon inﬂammation almost always and isolated
small bowel involvement rarely if not never is associated with PSC
Given these observations, the liver involvement seen in AISC with con-
current gut inﬂammation is predominantly related to colon inﬂamma-
tion seen in these patients. In that case, the importance of small bowe
mucosal breaks in the pathogenesis remains unclear. What relevance
do these have in understanding disease pathogenesis?
Aswe know,most patientswith PSC have a colitis,which is classiﬁed
as UC (Navaneethan and Shen, 2010; Loftus et al., 2005; Navaneethan,
1311U. Navaneethan / EBioMedicine 2 (2015) 1310–13112014). This study clearly shows that in patients with AISCwhichmay be
related to PSC have identical forms of colitis; however 39% also have
small bowel erosions. This pattern ismore representative of CD like pre-
sentation. These observations suggest that IBD associatedwith liver dis-
eases such as PSC or AISC need to be classiﬁed as separate disease entity
rather than being clustered as classic UC or CD. Also, the pathogenesis
and clinical outcomes are likely different from patients with classic UC
and/or CD. The study did have limitations as long-term clinical data on
outcomes were not available. It would have been interesting if the fol-
low-up clinical data was obtained in all these patients with AISC to un-
derstand the long-term disease progression including risks of surgery
and cancer in the colon and provide comparison data with PSC patients.
The liver–gut crosstalk could also explain the beneﬁcial effect of oral
vancomycin in patients with PSC, which could also work in AISC. A pre-
vious study had shown that peripheral levels of regulatory T (Treg) cells
are increased in patients treated with oral vancomycin (Davies et al.,
2008).
To summarize, the study by Bjarnason et al. (Bjarnason et al., 2015)
has given new insight on the potential interaction of the gut–liver axis,
and several important clinical observations on the association of AISC
and PSC and IBD.Wehavemade progress in understanding liver disease
in IBD patients. Until we clarify the pathogenesis, we should consider
using the term IBD associated with liver diseases rather than UC or CD
until we continue to untangle the mystery of the liver–gut crosstalk in
these patients.
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